BioCentury
ARTICLE | Finance

Delivering takeouts

25th annual Buyside View sees investors eyeing mid-cap M&A targets in 2017

December 31, 2016 12:53 AM UTC

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets.

“The main theme playing at the moment is investors like us are looking more and more to M&A plays rather than clinical data,” said HBM Partners’ Ivo Staijen. “That’s because we have had some pretty bad disappointments this year, and we haven’t seen any new big classes of drugs being launched since HCV.”...